Upcoming event
Masterclass on Focal therapy for localised prostate cancer
Back

Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy

  • Sargos P.,
  • Guerif S.,
  • Fraisse J.,
  • Meyer E.,
  • Supiot S.,
  • Lagneau E.,
  • Deniaud-Alexandre E.,
  • Rochin P.,
  • Benyoucef A.,
  • Cartier L.,
  • Hamidou H.,
  • Hasbini A.,
  • Crehange G.,
  • Pommier P.,
  • De Laroche G.,
  • Pelissier S.,
  • Gross E.,
  • Fourneret P.,
  • Salomon L.,
  • Latorzeff I.